October 2010 Reports on two studies that demonstrate the promise of treating addiction with medications that alleviate drug-induced alterations in signaling by the neurotransmitter glutamate.
April 2010 Announces the appointment of Dr. Phil Skolnick as NIDA’s director of the Division of Pharmacotherapies and Medical Consequences of Drug Abuse.
Reports on several drugs that may ward off depression and anxiety, common withdrawal symptoms from cocaine, based on an animal study.
Reports on a new device that creates tiny painless punctures in the skin to allow medication to flow evenly from a skin patch into dermal capillaries and the bloodstream.
Reports on a study investigating the effectiveness of a combined therapy of disulfiram and naltrexone for people who abuse cocaine and alcohol.
Highlights results from a pilot study suggesting that lofexidine, an anti-hypertensive medication, can enhance success rates among patients taking maintenance naltrexone to avoid opioid relapse.
Reports on study results indicating a medication prescribed for schizophrenia and manic phases of bipolar disorder shows promise as a cocaine addiction treatment.
Highlights NIDA-funded research to develop vaccines against addiction to drugs such as cocaine, nicotine, phencyclidine (PCP), and methamphetamine.
Reports on a randomized controlled trial of HIV-infected men and women who, as a result of receiving selenium supplements, experienced lower HIV viral load and greater CD4 cell count.
Describes research to develop new compounds that match or exceed the pain relief provided by opioids while avoiding their shortcomings.